12/10/2018 18:00:33

NovuHealth Named No. 5 on Minneapolis/St. Paul Business Journal's Fast 50 List for Two Years Running

Company Is Top Healthcare Firm on List of the 50 Fastest-Growing Private Companies in the Twin Cities, with 230% Growth from 2015-2017

MINNEAPOLIS, Oct. 12, 2018 (GLOBE NEWSWIRE) -- NovuHealth, the healthcare industry’s leading consumer engagement company, today announced that for the second straight year, it has been recognized as one of the fastest-growing privately held companies in the Twin Cities. The firm is ranked No. 5 in the Minneapolis/St. Paul Business Journal's 2018 Fast 50 List, which represents revenue growth of 230% from 2015-2017. Last year, the company was also ranked No. 5 on the list. NovuHealth came in as the top-ranked healthcare firm on the list this year.

“We’re delighted to be recognized with this honor,” said Tom Wicka, CEO and co-founder of NovuHealth, “because it confirms that our clients and the broader market see considerable value in our strategy of engaging consumers in their own care. It is especially humbling to receive this distinction in a market like the Twin Cities, which is home to the most impressive healthcare innovation in the country."

Recognition on the Fast 50 list is the latest honor in what has been a banner year for NovuHealth. In August the company was named to the Inc. 5000 list of the fastest-growing private companies in the U.S. from Inc. magazine. NovuHealth came in as one of the 100 fastest-growing private healthcare firms in the country.

Earlier in the year NovuHealth was recognized by two separate publications as one of the best places to work in the state of Minnesota. The company appeared on Minneapolis/St. Paul Business Journal’s 2018 Best Places to Work list and was named one of the Top 150 Workplaces in Minnesota by the Star Tribune.

These 2018 honors follow a stellar 2017. Last year the company was a Minneapolis/St. Paul Business Journal 2017 Eureka! Innovation award winner, while also finishing at No. 5 on the publication's Fast 50 list. In addition, the company was recognized by Minnesota Business magazine in the Excellence in Data Analytics category of their Innovators in Health and Wellness Awards.

About NovuHealth

NovuHealth is the leading healthcare consumer engagement company, offering rewards and incentive programs that improve consumer health and plan performance. NovuHealth applies proven loyalty and data science strategies and leverages its deep industry and regulatory expertise to motivate high-value consumer activities. Headquartered in Minneapolis, NovuHealth has worked with nearly 40 health plans and served more than 15 million consumers across all 50 states. Learn more at novuhealth.com.

Nathaniel Hawthorne

novu@bocacommunications.com

661-965-0407

Novu.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Jun
PNDORA
Hvad er det for noget eklatant ævl.Hvis man sammenholder de store fondes indtog på det danske aktiem..
24
13 Jun
PNDORA
Jeg er meget imponeret over Jyske bank og i særdeleshed analytikkeren Janne Vincent Kjær. Kunne rest..
20
09 Jun
PNDORA
Ok ja. Og i Schweiz betaler hverken dem der arbejder eller firmaer noget særligt i skat og alligevel..
18
12 Jun
PNDORA
er i dag ude med en dødsdoms artikel omkring Pandora. Artiklen er skrevet af en velanset analytiker,..
17
12 Jun
NOVO-B
Novo Nordisk aktien er d.d. steget med 120 kr. siden d. 25. nov. 2016. Dvs. fra 226 til 346 kr. 💪 ..
17
10 Jun
VELO
https://clinicaltrials.gov/ct2/show/study/NCT03979365 Bliver også spændene, at se om Envarsus sna..
15
15 Jun
PNDORA
Udover den samme analyse blev offentligjort for snart 3 uger siden er det da glimrende at man igen, ..
14
13 Jun
PNDORA
Nå du mener som IKEA, KIA, Hyundai, Harald Nyborg, Jysk og alle de andre hvor ingen vil handle..;)Må..
13
13 Jun
 
Kildevand på flaske ligeledes. Forbyd det. Kildevand, der fragtes fra Frankrig og  Italien til Danma..
13
12 Jun
PNDORA
Uden at have noget kendskab til Per Hansen artiklen, så kan jeg med sikkerhed sige, at din kommentar..
13

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
2
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
FSIS Recall 069-2019 Foreign Matter Contamination: RUIZ FOODS PRODUCTS INC. RECALLS BACON BREAKFAST WRAP PRODUCTS DUE TO POSSIBLE FOREIGN MATTER CONTAMINATION
5
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 04:34:17
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-16 05:34:17 - 2019-06-16 04:34:17 - 1000 - Website: OKAY